{"id":"rosiglitazone-brl49653c","safety":{"commonSideEffects":[{"rate":"null","effect":"Fluid retention"},{"rate":"null","effect":"Weight gain"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Muscle pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Activation of PPARγ leads to increased insulin sensitivity and glucose uptake in the muscles, as well as decreased glucose production in the liver. This results in improved glycemic control and reduced risk of cardiovascular events.","oneSentence":"Rosiglitazone activates PPARγ, a nuclear receptor that regulates glucose and lipid metabolism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:46.327Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT00432679","phase":"PHASE3","title":"A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-24","conditions":"Diabetes Mellitus, Type 2","enrollment":149},{"nctId":"NCT00297063","phase":"PHASE3","title":"BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-11","conditions":"Diabetes Mellitus, Type 2","enrollment":350},{"nctId":"NCT00523913","phase":"PHASE3","title":"A Study Of BRL49653C For The Treatment Of Type 2 Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11","conditions":"Diabetes Mellitus, Type 2","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rosiglitazone (BRL49653C)","genericName":"Rosiglitazone (BRL49653C)","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rosiglitazone activates PPARγ, a nuclear receptor that regulates glucose and lipid metabolism. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}